Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05952557 · ClinicalTrials.gov registry record · Phase 3

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

A Phase 3 study of Breast Cancer, Early Breast Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
5,500
Enrollment target
20
Study locations

NCT05952557 is a Phase 3 study of Breast Cancer, Early Breast Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 5,500 participants. The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05952557, a Phase 3 study of Breast Cancer, Early Breast Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
5,500 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.

Conditions Studied

Breast Cancer, Early Breast Cancer

Interventions

  • DRUG Camizestrant
  • DRUG Tamoxifen
  • DRUG Anastrozole
  • DRUG Letrozole
  • DRUG Exemestane

Study Locations (20)

California

  • Research Site - Duarte
  • Research Site - Fountain Valley
  • Research Site - Greenbrae
  • Research Site - Irvine
  • Research Site - La Jolla
  • Research Site - Los Angeles
  • Research Site - Monterey
  • Research Site - Walnut Creek
  • Research Site - West Hollywood

Colorado

  • Research Site - Aurora
  • Research Site - Littleton
  • Research Site - Littleton

Arizona

  • Research Site - Phoenix
  • Research Site - Tucson

Alabama

  • Research Site - Dothan

Arkansas

  • Research Site - Fayetteville

Connecticut

  • Research Site - New Haven

Delaware

  • Research Site - Newark

District of Columbia

  • Research Site - Washington D.C.

Trial Details

FieldValue
Enrollment Target 5,500 participants
Start Date 2023-10-05
Est. Completion 2037-05-06
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05952557

The ClinicalTrials.gov registry entry for NCT05952557 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 5,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer, Early Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Camizestrant is the first listed.

NCT05952557 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Colorado, Arizona.

Frequently Asked Questions

What is clinical trial NCT05952557 about?

NCT05952557 is a clinical study titled "An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)". This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without c...

What is the current status of trial NCT05952557?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,500 participants. The study started on 2023-10-05. Estimated completion is 2037-05-06.

What conditions does trial NCT05952557 study?

This clinical trial studies the following conditions: Breast Cancer, Early Breast Cancer.

What interventions are being tested in trial NCT05952557?

The interventions under investigation include: Camizestrant (DRUG), Tamoxifen (DRUG), Anastrozole (DRUG), Letrozole (DRUG), Exemestane (DRUG).

Who is sponsoring clinical trial NCT05952557?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05952557 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer, Early Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer, Early Breast Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.